Experience of dolutegravir in HIV-infected treatment-naive patients from a tertiary care University Hospital in Ireland.
OBJECTIVE
Dolutegravir, an HIV integrase inhibitor, is a relatively new treatment option. To assess the tolerability, side effects, and time to viral decline to non-detectable in patients newly started on dolutegravir.


METHODS
Retrospective health care record of 61 consecutive HIV treatment-naive patients started on dolutegravir was reviewed and analysed on SPSS.


RESULTS
The mean initial viral load was 160826.05 copies/mL (range, 79-1,126,617 copies/mL). HIV viral load became non-detectable in 63.9% of patients on dolutegravir within 3 months. In all, 60.7% of patients reported no side effects on dolutegravir; 98.4% of the patients claimed full compliance to their antiretrovirals.


CONCLUSIONS
Dolutegravir was found to be efficacious and well tolerated in HIV-infected treatment-naive patients.
Infectious Diseases Department, Mater Misericordiae University Hospital, Dublin, Ireland.
Sarmad
S
Waqas
Pharmacy Department, Mater Misericordiae University Hospital, Dublin, Ireland.
Mairead
M
O'Connor
Pharmacy Department, Mater Misericordiae University Hospital, Dublin, Ireland.
Ciara
C
Levey
Infectious Diseases Department, Mater Misericordiae University Hospital, Dublin, Ireland; University College Dublin, Dublin, Ireland.
Paddy
P
Mallon
Infectious Diseases Department, Mater Misericordiae University Hospital, Dublin, Ireland.
Gerard
G
Sheehan
Catherine McAuley Education & Research Centre, Mater Misericordiae University Hospital, Dublin, Ireland.
Anjali
A
Patel
Catherine McAuley Education & Research Centre, Mater Misericordiae University Hospital, Dublin, Ireland.
Gordana
G
Avramovic
Infectious Diseases Department, Mater Misericordiae University Hospital, Dublin, Ireland; University College Dublin, Dublin, Ireland; Rotunda Hospital, Dublin, Ireland.
John S
JS
Lambert
HIV; Pharmacoepidemiology/drug safety; dolutegravir; integrase inhibitor; naive; tolerability; viral load